The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D ...

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...

Novo Nordisk’s Ozempic (semaglutide) has been approved by the US Food and Drug Administration (FDA) to reduce the risk of ...

BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) shares, maintaining an Outperform rating and a $105.00 price target. This confirmation followed the U.S. Food and Drug ...

Most Wall Street professionals obsess over short-term returns. However, patient individual investors who buy and hold leading ...

An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.

Swiss biopharma company BioVersys said on Wednesday it had launched an initial public offering on the SIX stock exchange priced at 36 Swiss francs ($39.84) per share.

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

North Carolina achieved a record-breaking year for life sciences investments in 2024. Twenty-five companies announced ...